CITATION — REFERENCE ENTRY
strong-recommendations · fitzgerald-2020-acr-gout-guideline
- Citation
- fitzgerald-2020-acr-gout-guideline
- Claim ID
- strong-recommendations
- Assertion
- The ACR guideline's strong recommendations include allopurinol as preferred first-line urate-lowering therapy (including in chronic kidney disease stage 3 or worse), a low starting dose, a treat-to-target strategy with a serum urate goal below 6 mg/dL, anti-inflammatory prophylaxis for at least 3–6 months when starting therapy, and colchicine, NSAIDs or glucocorticoids for flares.
- Quote
allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage ≥3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (≤40 mg/day); and a treat-to-target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of [less than] 6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for a duration of at least 3–6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended.
- Quote language
- en
- Locator
- section: Abstract: Results
Available in